NCRI 2016 | Overview of the PD-1/PD-L1 research presentation

Lieping Chen, MD, PhD of Yale School of Medicine, New Haven, CT gives an overview of his talk on PD-1/PD-L1 molecular pathway research. For almost 20 years, Prof. Chen and his team have studied the PD-1/PD-L1 pathway, from cloning the molecules, identifying their function and role in the cancer setting, all leading to a development of anti-PD-1 and anti-PD-L1 therapies. Prof. Chen mentions that these therapies are used in patients when other conventional therapies failed, but he expects this cancer immunotherapy to have a broader application in the future, including early stage diseases. Recorded at the 2016 National Cancer Research Institute (NCRI) Conference in Liverpool, UK.